arrow
K

Kari C. Nadeau

stanford medicine
H指数:109
被引数:4.4万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

ARIA-EAACI 2025: Person-Centred, Digitally Enabled and Artificial Intelligence-Assisted Change Management in Airway Diseases

ARIA-EAACI 2025:气道疾病中以患者为中心、数字化赋能和人工智能辅助的变革管理

2026-09-030
OAAI
Common Food Emulsifiers Impair Epithelial Barrier Integrity and Trigger Pro-Inflammatory Responses and IgE Production

常见食品乳化剂损害上皮屏障完整性并触发促炎反应和IgE产生

2026-08-100
OAAI
Virus reactivation in acute and long COVID-19

急性期与长期新型冠状病毒肺炎中的病毒再激活

Nature
IF48.5
2026-08-050
OA
EAACI Guidelines on Environmental Science for Allergy and Asthma—Evidence-Based Recommendations for Prevention and Public Health Action to Mitigate the Impact of Pollen Exposure on Respiratory Allergy

欧洲过敏与临床免疫学会关于环境科学对过敏和哮喘的指南——基于证据的建议:为预防及公共卫生行动以减轻花粉暴露对呼吸道过敏的影响

2026-06-260
PRE
Levels and Sources of Airborne Volatile Organic Compounds in Fifty Homes Following the 2025 Los Angeles Wildfires

2025年洛杉矶野火后五十户家庭中空气挥发性有机化合物的水平和来源

2026-06-120
PRE
Leveraging Artificial Intelligence in Allergy, Asthma, and Immunology With Environmental Exposures

利用人工智能在过敏,哮喘和环境暴露的免疫学

2026-06-030
OA
Corrigendum to ‘Skin as the target for allergy prevention and treatment’ [Annals of Allergy, Asthma & Immunology, Volume 133, Issue 2 (2024) 133–143]

勘误:‘Skin as the target for allergy prevention and treatment’ [Allergy, Asthma & Immunology学报,第133卷,第2期(2024年)133–143页]

2026-03-300
OAAI
Risk and Protective Factors for Infection, Severe Disease, and Mortality in Epidemic Respiratory Viruses

感染、重症疾病及死亡在流行性呼吸道病毒中的危险因素和保护因素

2026-03-260
OAAI
Polyethylene Terephthalate Micro and Nanoplastics Induce Oxidative and Endoplasmic Reticulum Stress, Compromising Intestinal Epithelial Integrity and Viability

聚对苯二甲酸乙二醇酯微塑料和纳米塑料诱导氧化应激和内质网应激,破坏肠道上皮完整性和存活能力。

2026-03-250
OAAI
Empiric azithromycin alters the upper respiratory microbiome and resistome without anti-inflammatory benefit in COVID-19

经验性阿奇霉素改变了COVID-19患者上呼吸道微生物组和耐药组,但无抗炎益处。

2026-03-160
OAAI
Author Correction: Machine learning models predict long COVID outcomes based on baseline clinical and immunologic factors

作者更正:机器学习模型根据基线临床和免疫学因素预测长新冠结局

2026-02-230
OAAI
Efficacy and Safety of Ligelizumab in Individuals With Confirmed Peanut Allergy

Ligelizumab在确认花生过敏的个体中的疗效和安全性

2026-01-200
PRE
Machine learning models predict long COVID outcomes based on baseline clinical and immunologic factors

机器学习模型根据基线临床和免疫学因素预测长新冠结局。

2026-01-030
OAAI
A phase 2 randomized controlled trial using biologics to improve multi OIT outcomes (COMBINE): design; rationale; and methods

一项使用生物制剂改善多OIT结局的2期随机对照试验(COMBINE):设计;理由;和方法

2025-12-180
OAAI